Literature DB >> 8035998

Detection of cellular proteins that interact with the NF2 tumor suppressor gene product.

H Takeshima1, I Izawa, P S Lee, N Safdar, V A Levin, H Saya.   

Abstract

The neurofibromatosis type 2 (NF2) gene was recently cloned, and the protein it encodes (merlin) was revealed to belong to a family of proteins that link cytoskeletal components with proteins in the cell membrane. To elucidate the biological function of merlin, we produced a bacterial fusion protein consisting of glutathione S-transferase and merlin and used it to detect five merlin-binding cellular proteins, designated p165, p145, p125, p85 and p70, by a protein-binding assay. p165 and merlin were phosphorylated on serine/threonine residues, and immunoprecipitation showed that p85 bound the native form of merlin. Although the entire merlin-ezrin-radixin-moesin (MERM) homology domain of merlin was found to be essential for binding to all five proteins, the MERM homology domains of ezrin and moesin did not bind to any of the five proteins. Since most reported NF2 mutations are in the region we determined was necessary for binding, the mutations probably impair binding. Therefore, the formation of the protein complex is probably crucial for tumor suppression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035998

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.

Authors:  A I McClatchey; I Saotome; K Mercer; D Crowley; J F Gusella; R T Bronson; T Jacks
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

2.  Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.

Authors:  Hansoo Lee; Donghwa Kim; Han C Dan; Eric L Wu; Tatiana M Gritsko; Chuanhai Cao; Santo V Nicosia; Erica A Golemis; Wanguo Liu; Domenico Coppola; Steven S Brem; Joseph R Testa; Jin Q Cheng
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

3.  Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

Authors:  R P Stokowski; D R Cox
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

4.  Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.

Authors:  L Goutebroze; E Brault; C Muchardt; J Camonis; G Thomas
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

5.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

6.  On Arachnoid Villi and Meningiomas: Functional Implication of Ultrastructure, Cell Adhesion Mechanisms, and Extracellular Matrix Composition.

Authors:  Tetsumori Yamashima
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

7.  Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton.

Authors:  M A den Bakker; M Tascilar; P H Riegman; A C Hekman; W Boersma; P J Janssen; T A de Jong; W Hendriks; T H van der Kwast; E C Zwarthoff
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

8.  Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase.

Authors:  Y Fukata; K Kimura; N Oshiro; H Saya; Y Matsuura; K Kaibuchi
Journal:  J Cell Biol       Date:  1998-04-20       Impact factor: 10.539

9.  The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations.

Authors:  Jiaojiao Deng; Lingyang Hua; Tao Han; Mi Tian; Daijun Wang; Hailiang Tang; Shuchen Sun; Hong Chen; Haixia Cheng; Tao Zhang; Qing Xie; Lixin Wan; Hongda Zhu; Ye Gong
Journal:  Neurooncol Adv       Date:  2020-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.